UCB SA
Suletud
160.55 0.34
Ülevaade
Aktsiahinna muutus
24h
Min
160.55
Max
161.5
Sissetulek | 104M |
---|---|
Müük | 127M 2.8B |
P/E Sektori keskmine | 26.67 |
Aktsiakasum | 2.09 |
Kasumimarginaal | 3.728 |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +19.23 upside |
Turukapital | -180M 31B |
---|---|
Eelmine avamishind | 160.21 |
Eelmine sulgemishind | 160.55 |
Uudiste sentiment
By Acuity
17%
83%
UCB SA Graafik
Seotud uudised
UCB SA Prognoos
Hinnasiht
By TipRanks
19.23% tõus
12 kuu keskmine prognoos
Keskmine 94.86 EUR 19.23%
Kõrge 125 EUR
Madal 74 EUR
Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
Uudiste sentiment
Väga tugevad tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
EBITDA
Ärikasum
$
Ettevõttest UCB SA
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.